Unlocking Reimbursement for Digital Therapeutics
Unlocking Reimbursement for Digital Therapeutics
Insights from Adam Skali and EIT Health Innovator’s Community Spain
The healthcare landscape is undergoing a digital revolution, with Digital Therapeutics (DTx) at the forefront. These software-driven, evidence-based interventions are reshaping how diseases are managed, treated, and prevented. However, despite their promise, DTx faces a significant hurdle: achieving reimbursement. Adam Skali, presenting the work of the EIT Health Innovator’s Community in Spain, delved into this challenge and its implications for startups in the sector.
"Reimbursement serves as a cornerstone for healthcare companies seeking to generate revenue, especially in Europe, where public healthcare systems dominate."
Why Reimbursement is Critical for Digital Health Startups
Reimbursement serves as a cornerstone for healthcare companies seeking to generate revenue, especially in Europe, where public healthcare systems dominate. According to Skali, startups unable to secure reimbursement lose access to a substantial portion of the market. This barrier has led to a downturn in investment for digital health and therapeutics, as investors remain wary of the unclear path to profitability. Without reimbursement, even the most innovative DTx solutions struggle to integrate into clinical practice, limiting their impact on public health.
To address this issue, the EIT Health Innovator’s Community Spain team developed a survey to identify the primary obstacles startups face in securing reimbursement. The survey findings will feed into a comprehensive report that maps out go-to-market strategies for DTx across Europe, with a focus on creating a clear guide to navigate the complexities of reimbursement.
The Rising Role of Digital Therapeutics
Digital Therapeutics represent a paradigm shift in healthcare by offering validated, software-based treatments. Unlike traditional pharmaceuticals, DTx must undergo rigorous clinical validation to prove their safety and efficacy. However, this is only the first step in their journey toward adoption. The crux of the challenge lies in reimbursement, as it determines whether these solutions can be integrated into public healthcare systems.
In Europe’s tax-funded healthcare environment, reimbursement is not just a financial mechanism—it’s a gateway to accessibility and trust. Without appropriate frameworks, even the most transformative DTx innovations risk being sidelined.
Health Technology Assessment (HTA): A Gateway for Reimbursement
Central to the reimbursement process is the Health Technology Assessment (HTA), a framework used to evaluate the clinical effectiveness, safety, and economic viability of new technologies. HTA is pivotal for DTx, as it ensures innovations meet the stringent requirements of public and private payers.
This report offer an in-depth look at Spain’s HTA framework, which, while robust, faces challenges in standardizing reimbursement for DTx. By analyzing Spain’s system, the report will provide a blueprint for how HTA can adapt to support digital health innovations.
Spain’s roadmap differs from other European nations, for example:
- Germany: The DiGA fast track has become a model for rapid DTx integration.
- France and Belgium: These countries have developed tailored pathways to foster DTx adoption.
The future of healthcare is digital, and securing reimbursement is the key to unlocking its full potential. Through thoughtful strategies and collaborative efforts, DTx can revolutionize patient care while ensuring sustainable growth for healthcare innovators.